Pluri Inc (PLUR) Share Price

“The first cost estimates that we have applying Pluri’s technology into the production of Kokomodo cacao are very promising and will give Kokomodo a tremendous competitive advantage in this vertical.”

Asked about scaling plant cell culture, he added: “From day one, we have been growing cells in packed bed reactors that allow us to achieve real scale in relatively small bioreactors as our system is 20 times more efficient than a [typical] steel bioreactor [where cells grow in suspension].

“Our plan is to move aggressively and quickly to bring these solutions to market and our first step is to use bioreactors with five chambers of 200 liters capable of producing hundreds of kilos of cocoa and coffee. We anticipate that in 2026 this system will be available from Pluri for manufacturing across our subsidiaries. So when I’m talking about scaling up, it’s not a 10-year process, this is something that we see coming and coming soon.”

He added: “We are already discussing with players in the [coffee and chocolate] industry that are showing very significant interest in our solutions.”

Weinstein explained: “This is one of those rare opportunities you find in life as an investor, when you look at the quality of the people and the technology, it’s quite unique. The potential is explosive.

https://agfundernews.com/is-plant-cell-culture-a-scalable-way-to-futureproof-cocoa-and-coffee

New Company Presentation !!!

https://pluri-biotech.com/presentation/

Wow cocoa now. First the pretend steaks, then pretend coffee and now pretend cacao. Pretty good for a pretend company that’s going to the pinks in a few months.

Kokomodo: This Israel-based company uses cell-cultured technology to navigate supply chain challenges by creating real, controlled, climate-resilient cocoa. This allows cocoa to be consistently produced year-round and anywhere in the world without relying on specific climates.

Pluri is acquiring a 71% stake in Kokomodo Ltd.

https://ir.mondelezinternational.com/news-releases/news-release-details/mondelez-international-selects-10-start-ups-participate-second

Yaky Yanay, Chief Executive Officer and President of Pluri. “We are pleased that Mr. Weinstein understands our mission and will take part in shaping our strategy as we progress. We believe that Mr. Weinstein’s equity investment will strengthen our financial foundation and allow us to advance our entry into the cultivated cacao market, with the goal of positioning Pluri as a leader in this sector, where demand is growing and alternative agricultural solutions are needed to feed our global population. We believe that the synergy between Kokomodo’s advancements in cell line development and Pluri’s industrial-scale production creates a strong foundation for innovation, positioning the company to lead the field of cultivated cacao and set new benchmarks in cultivated cacao technologies.”

IMO....Pluri Will Control The Cultured Chocolate Market ! $$$/b]

Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of Directors
Pluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading AgTech company focused on the production of cacao, subject to shareholder approval.

https://pluri-biotech.com/releases/pluri-secures-6-5-million-strategic-investment-at-premium-to-market-enters-cacao-market-through-acquisition/

Pluri CEO & President Yaky Yanay

Pluri CEO & President Yaky Yanay

Nasdaq has determined to grant the Company an extension of time to regain compliance with the Stockholders’ Equity Requirement until May 24, 2025.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported, on November 25, 2024, Pluri Inc., or Pluri or the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market, or the Stockholders’ Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.

On January 6, 2025, the Company submitted a plan to regain compliance, or the Compliance Plan. Based on the Compliance Plan, Nasdaq has determined to grant the Company an extension of time to regain compliance with the Stockholders’ Equity Requirement until May 24, 2025. If the Company fails to evidence compliance by the required deadline, the Company may be subject to delisting. At that time, the Company may appeal Staff’s determination to a Hearings Panel.

The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance the Company will ultimately regain compliance with all applicable requirements for continued listing.

Neither the Nasdaq Letter nor the Company’s noncompliance have an immediate effect on the listing or trading of the Company’s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol “PLUR”.

A non event, eh FDA?

MORE MAIT CELL INDICATIONS !!!

In some embodiments, there is provided a method for treating a subject suffering from an autoimmune disease or disorder, comprising administering to said subject a composition comprising the population of engineered IVB CAR-MAIT cells disclosed herein. In some embodiments, the engineered IVB CAR-MAIT cells are allogeneic to said subject. In some embodiments, the autoimmune disease or disorder comprises systemic lupus erythematosus (SLE), refractory SLE, pemphigus vulgaris, multiple sclerosis, type I diabetes, rheumatoid arthritis, celiac disease, pernicious anemia, inflammatory myopathies, myasthenia gravis, or adrenalitis, or a combination thereof.
In other embodiments, there is provided a method of treating a subject infected with a pathogen, comprising administering to the subject a composition comprising a population of placental IVB CAR-MAIT cells, wherein the IVB MAIT cells are allogeneic to said subject.

In certain embodiments, these IVB MAIT cells do not comprise an exogenous antigen receptor. In some embodiments, the pathogen is a bacterial pathogen, a viral pathogen, or a fungal pathogen. In certain embodiments, a bacterial pathogen comprises an antibiotic resistant bacteria or bacterial treatment resistant bacteria. In some embodiments, a bacterial pathogen comprises a

Mycobacterium tuberculosis bacteria. In some embodiments, a fungal pathogen comprises an invasive Aspergillus. In some embodiments, a viral pathogen comprises a cytomegalovirus, a hepatitis B virus, or a hepatitis C virus. In some embodiments, the infectious condition treated by a method disclosed herein, is limited to site specific infections, for example wherein an infection is limited to a specific site or organ. In some embodiments, an infection treated by a method disclosed herein comprises a post-surgical infection.

MAIT CELL PATENT !!!

In some aspects of the invention, the cell composition disclosed herein is for use in therapy. In some optional embodiments, the cell composition may be used for treating a subject having a tumor or malignancy. Exemplifying use of the cell composition of the invention is for a subject afflicted with a tumor such as, but not limited to: blood cancer, melanoma, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, pancreatic cancer, prostate cancer, uterine cancer, cervical cancer, bladder cancer, stomach cancer, head and neck cancer, brain cancer, skin cancer and sarcoma.

In some aspects of the invention a method of treating a subject having a tumor or malignancy is provided, wherein the method comprises administering to the subject a cell composition according to any optional embodiment as defined above. The tumor treated may be for example, blood cancer, melanoma, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, pancreatic cancer, prostate cancer, uterine cancer, cervical cancer, bladder cancer, stomach cancer, head and neck cancer, brain cancer, skin cancer and sarcoma. Preferably, but not necessarily, the cell composition for treating the subject is adapted for cell therapy and the population comprises at least 109 viable cells, of which at least 90% are TCRVa7.2+ CD161hlgh.

In some embodiments, the engineered placental MAIT cells used for treating the subject are allogeneic to said subject. In other options, the engineered placental MAIT cells are partly histocompatible with the subject, or the engineered placental MAIT cells are not histocompatible with the subject.

In some aspects of the invention, a method of treating a subject infected with a pathogen is provided. The pathogen may be either one of a bacterial pathogen, viral pathogen, or a fungal pathogen, and the method comprises administering to the subject a cell composition according to any suitable optional embodiment as defined above.

In some additional aspects of the invention, method of treating a subject suffering from a fibrotic disease or condition, method of treating a subject suffering from a senescence-associated disease or condition, method of treating a subject having an allogeneic transplantation, method of treating a subject suffering from an autoimmune disease or disorder, are provided, wherein all methods above comprising administering to the subject in need a cell composition according to any suitable optional embodiment as defined above.

Yet, in accordance with additional aspects of the invention, a method of treating a subject infected with a pathogen is provided, the method comprising administering to the subject a composition comprising a population of MAIT cells derived from placenta. The population of MAIT cells according to this embodiment is not engineered MAIT cells, and the cells do not express exogenous CAR. The pathogen may be for example, a bacterial pathogen, a viral pathogen, or a fungal pathogen. In some specific examples the bacterial pathogen may comprise a Mycobacterium tuberculosis bacteria. In some embodiments, the bacterial pathogen comprises an antibiotic resistant bacteria or bacterial treatment resistant bacteria. In some other specific examples, the fungal pathogen may comprise an invasive Aspergillus. In some further examples, the viral pathogen may comprise a cytomegalovirus, a hepatitis B virus, or a hepatitis C optionally the infection is as a result of a post-surgical infection. Preferably, but not necessarily, the MAIT cells used for treating the subject according to this aspect of the invention are allogeneic to said subject.

2 Very Important Pluri MAIT Cell Patents Posted Today !!!

https://patentscope.wipo.int/search/en/result.jsf?_vid=P11-M5ZHNP-55415

Yaky Yanay: Revolutionizing Biotech with Pluri's Cell-Based Solutions

Cellular Agriculture Redefines The Future Of Coffee

https://stir-tea-coffee.com/tea-coffee-news/cellular-agriculture-redefines-the-future-of-coffee/

They pretend cured Covid, IC, ICS, Beurgers, Solid Tumours, Preeclampsia, ARS, Hip and others I’m sure over forgotten over the decades. So why not pretend cure cancer too.

Pretend all the way to the pinks with -$10,000,000.00 in shareholder equity.

Can a Placenta Cure Cancer?

BIU’s collaboration with biotechnology company Pluri suggests it can

https://www.biu.ac.il/en/article/582414#:~:text=At%20the%20heart%20of%20this%20research%20lies%20a,MAIT%20cells%20from%20placentas%20donated%20by%20healthy%20women.

Should only see about another 4 or 5 of these before they finally shut this company runs out of money. Took 25 years but 2025 will mark the end of this legal scam. Those 150 employees plus will milk every last penny they can, and most likely steal whatever they can from the office. They were taught well by the head clowns.

-$10,000,000.00 in shareholder equity.
Trading at fresh ALL TIME lows
Nuf said

January Company Presentation !!!

https://pluri-biotech.com/presentation/

New all time lows to go along with the nearly -10,000,000.00 in shareholder equity. Keep an eye out on the Israeli Kijiji. They’re going to be selling office furniture real soon.

How they gonna overcome almost -$10,000,000.00 in shareholder equity. The one that’s gonna get them on the pinks. But the $500,000,000.00 that they’ve blown with nothing to show for it becomes irrelevant when you look at the big picture. Like the good ole Zzatt used to say, “WE GOT ZZIENTISTS” wonder how his 200,000 shares are doing.

“For us, it’s not just a theoretical exercise, we can produce hundreds of kilos in our labs. This is not something that we intend to develop in five years’ time; we know how to scale this process.” Yaky Yanay, CEO, Pluri

https://agfundernews.com/eggs-coffee-chocolate-and-the-culture-wars-foodtech-in-2024

PLUR under $5

Not when you’re around - $9 million in shareholder equity. That’s what happens when you blow through half a billion dollars with literally zero to show for it. Even the pr says ARS will s all they got on the go and we all know they failed on that one already.

Clowns are just about done with their schemes to dupe investors out of their money.

This Bodes Well For The Space !!!

The FDA granted approval of Ryoncil to Mesoblast, Inc.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host

-$5,283,000 shareholder equity as of Sept 30th. They lost over $6,000,000 last quarter so by now with a bit more than half a month to go in this quarter, they should be hitting -$10,000,000 in shareholder equity.

Next stop…the pinks.

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

https://pluri-biotech.com/releases/u-s-national-institutes-of-health-to-fund-4-2-million-contract-to-advance-development-of-pluris-plx-r18-in-conjunction-with-u-s-dod-as-a-medical-countermeasure-for-hematopoietic-acute-radi/

4.8315 -0.1685 (-3.37%)
As of 9:45:46 AM EST. Market Open.
Volume 30,082
Avg. Volume 25,828
Wow, the market sure is impressed!

Huge Pluri Biotech Patent Posted Today !!!

Coffee/Cacao And Every Other Plant On The Planet !!!

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024252382&_cid=P12-M4LD2S-44544-1

Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal
https://pluri-biotech.com/releases/pluristem-receives-response-from-u-s-barda-for-acute-radiation-syndrome-research-proposal/

At this time, BARDA has chosen not to move forward with the funding of the current proposal. The decision is based on BARDA’s technical considerations as determined by a Technical Evaluation Panel.
Other factors considered by BARDA included BARDA’s current strategic needs, availability of funds and resources, and an aim to balance BARDA’s current portfolio. In its response, BARDA encouraged and invited Pluristem to participate in future relevant BARDA opportunities.

“While we had hoped to receive the funding of the proposal, we understand that at this time there are a set of parameters that led BARDA to this decision.
We will continue to advance our current ARS projects with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. Department of Defense (DOD), Fukushima Hospital and the University in Japan and pursue additional opportunities and collaborations in this area.

BARDA rejects Pluristem's request for radiation study funding
By Nick Paul Taylor Mar 3, 2020 8:40am
https://www.fiercebiotech.com/biotech/barda-rejects-pluristem-s-request-for-radiation-study-funding

They had to evaluate? Lmao. They started this ARS crap a decade ago. They need to “evaluate”. That’s absolutely hilarious.

Wheres the beef? Thought they were on the cusp of growing steaks and milk and coffee beans. Can’t forget about all those things too. Boy you’d think with all the presentations on their partnership with another Israeli company would have something to announce by now no?

Maybe the whopping $300k they made last quarter will suffice. Since they’re nominated for CDMO shortlist and actually announce this massive news release, I’m sure everyone’s clamouring to use these clowns.

They’ve been legally scamming people for 25 years now. An accomplishment I’m not sure can be touched. To milk half a BILLION off of shareholders and after 25 years have revenues of $300,000 for a quarter, these guys should be locked up truly.

Karma to all involved in this fraud. Big fat karma.

Observe !!!

https://pluri-biotech.com/releases/pluri-evaluates-readiness-for-mass-production-of-plx-r18-for-acute-radiation-syndrome-amid-rising-nuclear-threat-concerns/

Why can’t you answer how they’re going to dog out of that -$5 million in shareholder equity. All the years you’ve said Scotty didn’t know. No w you can’t answer. What’s going on with you. At least you could make something up like you always do.

$5k shares traded. Laughable. Clowns know they’re cooked. I think they’re hoping for another pandemic so they can try and scheme another $50,000,000.00 out of people.

Did you not see the news today. They’ve been shortlisted to win CDMO of the year. They managed to do it with only $326k in revenue. All those big CDMO’s must be so jealous. Especially since they snagged the accountant turned CEO Kaki

Still nothing FDA on how they’re going to regain compliance. You know, the non compliance of being -$5,000,000 in shareholder equity. Are you concerned with them running out of money since their assets minus their liabilities brings them to that -$5 million mark.

All the beliebers in you really want to know. Especially zzatty boy. We got Zzientists!!!

3 Biotech Stocks Set to Skyrocket in 2025

https://www.investing.com/analysis/3-biotech-stocks-set-to-skyrocket-in-2025-200654842

Wow you’d think such a stand up clown like Kaki, would put in the presentation an asterisk beside the $27 mil in cash saying -$5,000,000 in shareholder equity.

Why you tryin to hide that Kaki? Why you not spinning it FDA? Remember…karma

December Company Presentation Is Out !!!

https://pluri-biotech.com/presentation/

No spin on Midas’ post on how Pluristem is in delinquency for their Nasdaq listing there now FDA? This one ain’t about falling under a buck. But how shareholder equity is at -$5,200,000.

Wow just a short 2 years ago shareholder equity was at $48,000,000. How did they blow through that so quickly. Or the $500,000,000 since inception?

How are they going to regain compliance? Going to have to do a raise of at least $7.5 million just to regain compliance. Then within a month, the 150 employees with fictitious titles will chew through that and lose compliance again. How oh how will they fix this one?

Kaki was hoping the pretend potential stockpiling for ARS was going to pump up the price so they can raise another $50 million. Or the second release in 7 years about those good ole solid tumours. Nothings working for the Kaki. The Chairman of the board that used to sell first aid kits for cars is out of ammo. I heard he’s taking pencils home every night and selling them on eBay. Trying to milk every last penny out of this pig.

How these clowns aren’t all in jail is beyond me. Even if not for breaking some law, just for being two of the most incapable CEO’s ever to exist. They should have gone belly up in 2020 if it weren’t for the gift they got aka Covid. That raise of $50 million certainly padded their pockets nicely. Maybe they should announce another Covid trial.

Freaking jokes, and hopefully the people who pumped this pig for decades, has karma knocking on their door real soon. Hope your kids are proud of you. Oh daddy, when I grow up I want to be a scammer just like you. Pathetic.

New Technology Addresses At-Risk Commodity Ingredients

By Nimrod Bar Zvi, Chief Commercial Officer, Pluri

https://foodindustryexecutive.com/2024/12/new-technology-addresses-at-risk-commodity-ingredients/

New Immune Cell Expansion Patent Published That Includes Gene Modification !!!

WOW !!!

In some further optional embodiments of the invention, the immune cells population is genetically modified by using gene modifying agents spiked into the bioreactor medium.

Step: 322, the immune cells are genetically modified in order to add or delete specific traits. Modifications such as the addition of new targeted or activation receptors or the deletion of specific receptors for self-recognition or the deletion of unwanted target receptors are used for transforming the immune cells for better treatments in different indications.

https://patentscope.wipo.int/search/en/detail.jsf?docId=US443345058&_cid=P22-M44845-38695-1

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 25, 2024, Pluri Inc., or Pluri or the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market, or the Stockholders’ Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.

Pursuant to the Nasdaq Letter, the Company has 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance and the Company intends to submit such a plan during this period. If it accepts the plan, Nasdaq can grant an extension of up to 180 calendar days from the date of the Nasdaq Letter to evidence compliance. In the event the plan is not accepted by Nasdaq, or in the event the plan is accepted and the 180-day extension period granted but the Company fails to regain compliance within such plan period, the Company would have the right to a hearing before an independent panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.

The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance that Nasdaq will grant the Company’s request for an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing.

Neither the Nasdaq Letter nor the Company’s noncompliance have an immediate effect on the listing or trading of the Company’s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol “PLUR”.

Oy - Vey

DoD Stockpiling Contract For PLX-R18 For ARS Must Be Coming ???

Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns

https://finance.yahoo.com/news/pluri-evaluates-readiness-mass-production-133000218.html

Climate Change Is Coming for these Food Staples, So Technology is Taking Farming into the Lab

https://techbullion.com/climate-change-is-coming-for-these-food-staples-so-technology-is-taking-farming-into-the-lab/

IMO....Pluri Is Going To Do Both Coffee & Chocolate !!! WOW !!!

Commodity Markets at Risk for Destabilization as Tech Takes Farming Into the Lab

https://www.investing.com/analysis/commodity-markets-at-risk-for-destabilization-as-tech-takes-farming-into-the-lab-200654186

Thursday: November 21st @ 9:00 AM EST Pluri CEO Investor Presentation

https://www.webcaster4.com/Webcast/Page/3075/51643

November Company Presentation !!!

https://pluri-biotech.com/presentation/

Placenta-Derived Mesenchymal Stromal-Like Cells Promote 3D-Engineered Muscle Tissue Differentiation and Vessel Network Maturation

https://onlinelibrary.wiley.com/doi/10.1002/smsc.202470045

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

https://finance.yahoo.com/news/brainstorm-cell-therapeutics-pluri-partner-110000497.html